Laurus Labs

The company has 4 business divisions, which are generic formulation (FDF), generic APIs, contract development and manufacturing (CDMO)-Synthesis, biotechnology^[10] and speciality chemicals.

In March 2020, Laurus Labs received US Food and Drug Administration approval to market hydroxychloroquine tablets. The company announced that it would supply hydroxychloroquine for clinical trials of preventive treatment of COVID-19.^[11]

Laurus Labs claims to be the "world's largest third party API supplier for anti-retrovirals" and has one of the largest^[12] HiPotent API capacities in India^[13] The company also makes Dolutegravir/lamivudine/tenofovir, a medication for HIV/AIDS,^[14][15] and hydroxychloroquine tablets, which are used to treat certain types of malaria.^[16]

The company also manufactures oncology and cardiovascular APIs.^[17] Laurus Labs supplies (APIs) to nine of the 10 largest generic pharma companies in the world.^[17]

Laurus Synthesis is the company's CDMO subsidiary.^[18] The US, European Union and Japan are the three most important markets for Laurus Synthesis.^[19]

Laurus Bio is the company's biotechnology subsidiary. Laurus Labs entered the biotechnology sector in 2020, by acquiring the Indian biotech company, Richcore.^[20] Post the acquisition, Richcore was renamed to Laurus Bio Pvt Ltd, and became a subsidiary of Laurus Labs.^[20] As of 2022, Laurus Bio has put into operation a 180 kilolitre fermentation capacity in food proteins.^[21][22]

• "Laurus Labs subsidiary incorporates Laurus Ingredients; stock gains 1%". www.indiainfoline.com. Retrieved 20 January 2021.
• "Laurus Labs: Diversification to speed up in FY23; add on declines". Moneycontrol. 3 May 2021. Retrieved 3 May 2021.
• "Laurus Labs is already halfway past its $1 billion revenue target and has new capacities and products to back up its growth plan". Moneycontrol. 4 May 2021. Retrieved 4 May 2021.